Special Issue

HIV-Associated Immune Activation and Inflammation: Current Understanding and Future Perspectives

Message from the Guest Editor

Authors are invited to submit their original research, communications, and review articles to *Biomedicines*. Potential topics include, but are not limited to:

- Strategies for the modulation of inflammation in PLWH:
- In vivo and in vitro models of immune modulation during HIV;
- HAND: HIV-associated neurocognitive disorder;
- Drivers of systemic inflammation in PLWH;
- Drivers of neuro-inflammation in PLWH:
- Strategies to modulate the HIV reservoir (activation, inactivation);
- Cellular therapies for HIV cure;
- The role of cytokines in HIV persistence and impaired immunity;
- Dissecting the mechanism of inflammation;
- Dissecting the mechanisms of viral persistence.

Guest Editor

Dr. Susan Pereira Ribeiro

Emory Vaccine Center, Pathology Advanced Translational Research Unit (PATRU), Department of Pathology, Winship Cancer Institute, Emory University, School of Medicine, Atlanta, GA 30322, USA

Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/192958

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/ biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).